246,348 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Acquired by Systematic Financial Management LP

Systematic Financial Management LP purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 246,348 shares of the company's stock, valued at approximately $9,147,000. Systematic Financial Management LP owned approximately 0.51% of Amphastar Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after buying an additional 871 shares during the period. Tower Research Capital LLC TRC grew its holdings in Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after acquiring an additional 348 shares during the period. Huntington National Bank grew its holdings in shares of Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after acquiring an additional 361 shares during the period. Finally, TD Private Client Wealth LLC raised its stake in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after buying an additional 388 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 0.3%

AMPH stock traded down $0.08 during trading on Friday, reaching $24.12. The stock had a trading volume of 136,376 shares, compared to its average volume of 477,513. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a fifty day moving average price of $25.26 and a 200 day moving average price of $33.24. The company has a market capitalization of $1.15 billion, a P/E ratio of 8.05, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96.

Analyst Ratings Changes

Several brokerages recently commented on AMPH. Wells Fargo & Company dropped their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $32.33.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 5,231 shares of company stock valued at $142,752 over the last three months. 27.50% of the stock is owned by insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.